About
Antibody-Drug Conjugates
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibodyChina
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
255
By Phase
PHASE2: 3EARLY_PHASE1: 1PHASE1: 1
By Status
RECRUITING: 2NOT_YET_RECRUITING: 1TERMINATED: 1COMPLETED: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06651541Lead Sponsor
Evaluation of the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder
PHASE2Not yet recruiting
140 participants
Started: Jul 1, 2025 · Completed: Jul 31, 2026
NCT06116045Lead Sponsor
Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder
PHASE2Recruiting
30 participants
Started: Oct 1, 2024 · Completed: Mar 31, 2025
NCT05558007Lead Sponsor
Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
PHASE2Recruiting
72 participants
Started: Nov 22, 2023 · Completed: Jan 31, 2025
NCT05384379Lead Sponsor
Efficacy and Safety Evaluation of BZ371B in ARDS Patients
EARLY_PHASE1Terminated
1 participants
Started: Nov 23, 2022 · Completed: Mar 3, 2023
NCT05332340Lead Sponsor
Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered
PHASE1Completed
12 participants
Started: Nov 16, 2022 · Completed: Nov 30, 2022
Locations (1)
Headquarters
Hangzhou, China
Map
Loading map...